Taken together, these findings suggest that the effects of GLP-1RAs in breast cancer are context-dependent and may vary according to tumor subtype and exposure conditions, warranting caution when extrapolating high-dose preclinical observations to clinical safety
In comparison, there were five patients with diabetes without gastroparesis amongst the GLP-1RA users (Table 1)
Source: Polaris Market Research Analysis Off-Label Use and Counterfeit Semaglutide Regulatory and Market Implications The FDA has expressed growing concern over the off-label use of unapproved and compounded semaglutide
Accessed on April 21, 2026
Growth of the segment has been attributed to strong clinical outcomes associated with this class of drugs, including improved glycemic control, reduced appetite, and significant weight reduction
D51.2 Transcobalamin II Deficiency Use for congenital transcobalamin II deficiency, a rare inherited disorder diagnosed in infancy